Cheng-Han Tsai

Title: Cheng-Han Tsai: Innovator in Matrix Metalloproteinase Inhibitors

Introduction

Cheng-Han Tsai is a notable inventor based in Newark, DE (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of matrix metalloproteinase (MMP) inhibitors. His work focuses on innovative compounds that have the potential to treat various diseases.

Latest Patents

Cheng-Han Tsai holds 2 patents related to matrix metalloproteinase inhibitors. His latest patents describe hydantoin-based compounds that are useful as inhibitors of matrix metalloproteinases, specifically targeting macrophage elastase (MMP-12). These patents detail compositions and methods for using these compounds to inhibit MMP-12 and address diseases mediated by this enzyme, including asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Career Highlights

Cheng-Han Tsai is currently associated with Foresee Pharmaceuticals USA, Inc. His work at this company has been instrumental in advancing research and development in the pharmaceutical sector. His innovative approach to drug development has garnered attention in the scientific community.

Collaborations

Cheng-Han Tsai has collaborated with notable colleagues, including Wenjin Yang and Kai-Wei Chang. These collaborations have contributed to the success of his research and the advancement of their shared goals in the field of pharmaceuticals.

Conclusion

Cheng-Han Tsai is a prominent inventor whose work in matrix metalloproteinase inhibitors has the potential to impact the treatment of various serious diseases. His contributions to the field are significant and continue to inspire further research and innovation.